11 August 2017 | News
The acquisition expands the Group’s presence within the US healthcare market and increases US sales by more than double.
Courtesy- The blue diamond gallery
Tissue Regenix Group plc, a UK-based leading medical devices company in the field of regenerative medicine announced the completion of the acquisition of CellRight Technologies LLC, a US-based specialist in regenerative osteoinductive bone scaffolds.
The acquisition, expands the Group’s presence within the US healthcare market and increases US sales by more than double, bringing together two highly complementary technology and product platforms focused on soft-tissue regeneration and regenerative bone matrices, respectively.
TRX has built a portfolio of soft tissue products for use in wound care, orthopaedics and cardiac applications, based on its patented dCELL Technology with DermaPure, a decellularised dermal allograft for chronic and acute wound care, currently commercialised. CellRight, brings a complementary regenerative technology which is used to turn allograft bone into various malleable applications including, DBM Putty, strips, blocks and fibres, primarily for use in spine, orthopaedics and dental surgeries.
Leveraging the capabilities of CellRight Technologies’ existing tissue bank in San Antonio, TX, Tissue Regenix is set to launch its OrthoPure HT, decellularised human tendon, into the U.S. orthopaedics market in early 2018, which will initially address anterior cruciate ligament repair. This facility also provides the Group with a purpose built U.S. base to self-manufacture products utilising its patented dCELL process.